Special Issue "Redox State, Mitochondrial Metabolism and Autophagy in Cancer and Its Modulation by Antitumor Agents and Immunotherapy"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 190
Interests: mitochondria; reactive oxygen species; antioxidants
Special Issues, Collections and Topics in MDPI journals
Special Issue in Future Pharmacology: Mitochondria as Potential Target in Disease Therapy
Special Issue in Biomolecules: Metabolic Mechanisms in Renal and Cardiovascular Diseases
Special Issue in Foods: Polyphenols and Health Benefits
Several antitumoral treatments exert their function through changes in the redox state, mitochondrial metabolism, and autophagy process of the tumoral cells. Meanwhile, some types of cancer require certain reactive oxygen species (ROS) levels to grow and develop metastasis; other types of cancer need reduced ROS levels to induce metastasis. It should be noted that high ROS levels also induce cell death as ROS can overcome the cell tumor umbral of resistance to oxidative stress (OS). Thus, cancer progression may depend on ROS, but ROS overproduction could be a therapeutic target to induce cancer cell death. Moreover, OS can induce mitochondrial damage and its dysfunction and, consequently, cell death. Autophagy is a degradation process that can degrade these dysfunctional mitochondria to promote new mitochondria biogenesis; if this cellular mechanism is not functioning properly, the tumor decreases because of the accumulation of damaged organelles. Thus, redox state, mitochondrial dysfunction, and autophagy are key events for cancer and metastasis reduction, and the exploration of these processes is crucial for the induction of metastasis and cancer reduction. Moreover, the immune response of the cancer patient associated with the latter processes plays a fundamental role in cancer elimination. Reviews and original research manuscripts that explore the effects of ROS, OS, autophagy, and immune response related to cancer development and its elimination, including antitumor agents and immunotherapy, are welcome to this Special Issue.
Prof. Dr. José Pedraza Chaverri
Dr. Alfredo Cruz-Gregorio
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.